All Press Releases
PILA PHARMA publishes interim report January 1 – March 31, 2022
Malmö, April 26, 2022 PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for the period January – March 2021. The report can be found on the Company´s website: pilapharma.com SUMMARY OF YEAR-END REPORT First quarter (1 January – 31 March 2022) Revenue was SEK 535 kSEK (0) Operating loss (EBIT) was – 2 403 kSEK…
Pila Pharma AB tillkännager certifiering av API
Malmö, 25 april, 2022 Pila Pharma AB (PILA) tillkännager i dag att det studieläkemedel (non-GMP API) som ska användas vid tremånadres prekliniska studier har erhållit ett analyscertifikat och därmed är klart att använda. Som tillkännagavs i augusti 2021 lades tillverkningen av ett nytt XEN-D0501 API för de planerade prekliniska säkerhetsstudierna ut till Almac Group genom ett outsourcingavtal. Denna tillverkning är…
Pila Pharma AB announces certification of API
Malmö, Sweden, April 25, 2022 Pila Pharma AB (PILA) today announces that the study material (non-GMP API) to be used in three-month preclinical studies has received a certificate of analysis and is thus ready to use. As announced in August 2021, the production of a new XEN-D0501 API for the planned preclinical safety studies was outsourced to Almac Group. This…